Navidea

Navidea Biopharmaceuticals Inc is involved in the development and marketing of products for the detection and treatment of cancer. The company is developing several cancer diagnostics and tracing agents that can be used with these instruments. The combination of the two creates an activated cellular therapy (ACT), which is used to boost the immune system. The company is also involved in the development of blood flow measuring devices.In September 2016, Navidea executed a Letter of Intent (LOI) with Cardinal Health for the sale of all rights, title and interest to Navidea's Lymphoseek product for all FDA-approved, pending and future oncology diagnostic indications in North America. Under the terms of the LOI, Navidea would receive $80 million at closing and the total consideration to Navidea would be capped at $310 million. In November 2016, the agreement was signed. The transaction was to close in the first quarter of 2017.In December 2014, Navidea announced the formation of Macrophage